Today at their offices in Menlo Park, venture capital firm Kleiner Perkins Caufield & Byers is celebrating the third anniversary of the iFund. Technically, the fund started in March of 2008 alongside the first iPhone SDK, when the firm announced that it would be investing $100 million in iPhone a…
MENLO PARK, CA — June 2, 2011 – Kleiner Perkins Caufield & Byers (KPCB) today announced that James Huang, a ranking executive for several pharmaceutical industry giants over the last 20 years, has joined the firm as a partner in Shanghai, China. Huang will advise on life science investment opportunities in China.
“KPCB’s expanding presence in China provides a great vehicle for driving innovation in the region’s growing pharmaceutical markets,” said Huang. “I look forward to assisting entrepreneurs with their efforts to bring innovative new products to market.”
“With his extensive business development and operating experience, James will be a tremendous asset for innovators looking to develop successful pharmaceutical companies in China,” said Tina Ju, a managing partner and co-founder of KPCB China.
Huang joins KPCB from Vivo Ventures, a venture capital firm specializing in life science investments, where he was a managing partner. Prior to Vivo, Huang was president of Anesiva, a biopharmaceutical company focused on pain management treatments. He’s also held senior roles with Tularik, Inc., GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. He received an M.B.A. from Stanford Graduate School of Business and earned a B.S. degree in Chemical Engineering from University of California, Berkeley.